A ‘New Normal’ for Quality?

March 15, 2020

Rita C. Peters

Rita Peters is editorial director of Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Pharmaceutical Technology, Pharmaceutical Technology-03-15-2020, Volume 2020 eBook, Issue 1

Page Number: 4–5

With some FDA inspections on hold, will the US drug supply maintain its quality standards?

In February 2020, a report from FDA’s Office of Pharmaceutical Quality (OPQ) noted that, “Quite simply, the quality of our drug supply is better than ever before.” With some FDA inspections on hold, will the US drug supply maintain its quality standards? Plus, which new drug applications must now be filed as biologic license application?

Read this article in Pharmaceutical Technology’s March 2020 Regulatory Sourcebook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook and Reference, March 2020
March 2020
Pages: 4–5

Citation

When referring to this article, please cite it as R. Peters, “A “New Normal” for Quality?" Pharmaceutical Technology Regulatory Sourcebook and Reference eBook (March 2020).